{"analyses":[{"ciLowerLimit":"1.17","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.23","groupDescription":"The historical control included 10 medulloblastoma patients treated during 1998-2006 who would have been classified as intermediate risk according to SJYC07 criteria (section 13.1.3 of protocol).","groupIds":["OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"4.99"},{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.84","groupDescription":"The historical control included 14 medulloblastoma patients treated during 1998-2006 who would have been classified as high risk according to SJYC07 criteria (section 13.1.3 of protocol).","groupIds":["OG002"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.86"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.5","upperLimit":"91.3","value":"73.9"},{"groupId":"OG001","lowerLimit":"30.2","upperLimit":"63.6","value":"46.9"},{"groupId":"OG002","lowerLimit":"14.1","upperLimit":"47.5","value":"30.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"26"}],"units":"Participants"}],"description":"EFS was measured from the date of initial treatment to the earliest date of disease progression, second malignancy or death for patients who fail; and to the date of last contact for patients who remain at risk for failure. 1-year EFS estimates are reported by risk group. EFS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Medulloblastoma patients \\<3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm\\^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) \\[R0\\])","id":"OG000","title":"SJYC07 Low-risk Medulloblastoma Patients"},{"description":"SJYC07 medulloblastoma patients \\<3 years of age, no evidence of metastatic disease (M0), and either R0 resection with any other medullo histology other than histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN) (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of \\>1 cm\\^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group","id":"OG001","title":"SJYC07 Intermediate-risk Medulloblastoma Patients"},{"description":"SJYC07 medulloblastoma patients \\<3 years of age with evidence of metastatic disease","id":"OG002","title":"SJYC07 High-risk Medulloblastoma Patients"}],"paramType":"NUMBER","populationDescription":"Eligible medulloblastoma patients who received any methotrexate were included in this analysis. Hazard ratios with 95% confidence intervals are reported and compare SJYC07 patients to historical controls in each risk group. As there were too few low-risk historical controls, no hazard ratio is included for the low-risk group.","reportingStatus":"POSTED","timeFrame":"From date on treatment until date of first event (progression, second malignancy or death) or until date of last contact, assessed up to 10 years","title":"Event-free Survival (EFS) Compared to Historical Controls","type":"SECONDARY","unitOfMeasure":"Percent probability"}